课题基金 / 基金详情

Molecular Studies of Esophageal Adenocarcinoma

Molecular Studies of Esophageal Adenocarcinoma
食管腺癌的分子研究
批准号:
7224840
负责人:
DAVID George BEER
金额:
$30.59万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-06-05 至 2010-04-30
关键词:
3q267q21AdenocarcinomaAdenocarcinoma CellAffectAgarAmino Acid SequenceAngiogenesis InhibitionApoptosisAreaBarrett&aposs AdenocarcinomaBeerBiological AssayBiological ModelsCandidate Disease GeneCell LineCell ProliferationCell SurvivalCellsCellular MorphologyChromosome MappingClinicalCloningComputersCytotoxic agentDNADNA MarkersDNA amplificationDevelopmentDiseaseDisease ProgressionEarly DiagnosisEpidermal Growth Factor ReceptorEsophagealEsophageal AdenocarcinomaEsophageal TissueEventExpressed Sequence TagsFreezingFrequenciesFundingGelGene AmplificationGene ExpressionGene Expression ProfilingGene FamilyGene TargetingGenesGeneticGenome ComponentsGenome ScanGenomicsGoalsIn VitroIncidenceIndividualInhibition of ApoptosisInvasiveInvestigationLocationMalignant NeoplasmsMapsMessenger RNAMetaplasiaMethodsMolecularMusMutationNormal tissue morphologyNorthern BlottingNude MiceNumbersOligonucleotide MicroarraysOncogenesOutcomePathway interactionsPatientsPatternPeptide Sequence DeterminationPolymerase Chain ReactionProcessProtein OverexpressionResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRoche brand of trastuzumabSamplingScanningScreening procedureSequence AnalysisSiteSouthern BlottingStandards of Weights and MeasuresTechnologyTherapeuticTherapeutic InterventionTranscriptTransfectionTranslationsTumor TissueWorkbasecancer therapycarcinogenesiscell growthclinically relevantcomparativeexpression vectorimmortalized cellin vitro Modelinsightinterestmalignant breast neoplasmneoplasticnovelprogramstherapeutic targettooltumortumor progressiontwo-dimensional

项目摘要

项目成果

DAVID George BEER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goals of this renewal application are to identify important and potentially novel amplified cancer-related genes in esophageal adenocarcinomas, a deadly cancer that is increasing in incidence. The identification of genomic amplifications, and the resulting important genes over-expressed in these tumors, will provide significant insight into the molecular events associated with the development and progression of this disease. This work may provide new genetic tools for early detection, and potentially for identifying new avenues for therapeutic intervention. We have identified a number of potentially novel genomic amplification events in esophageal adenocarcinomas using the highly sensitive method of quantitative two-dimensional genomic scanning (2D gels) and using gene expression profiling with oligonucleotide arrays. The 2D-gel technology involves the comparative analysis of several thousand genomic restriction fragments derived from functional components of the genome between the normal and tumor tissue from an individual patient. The amplified and over-expressed genes encompassed in the amplicons are identified and characterized as we have successfully demonstrated. Utilizing well-defined chromosomal markers, a quantitative PCR assay and the DNA from large numbers of normal tissue-adenocarcinoma paired samples, we have identified the "minimal region of common amplification" for a number of specific amplicons for immediate analysis and other amplicons will be determined. The important amplified and over-expressed cancer-related genes and will be defined. Potential candidates may include known genes, uncharacterized expressed sequence tags, or genes isolated from genomic clones that map within the minimal region. The cancer-relatedness of novel genes will be examined using functional assays involving transfection into immortalized cells and the analysis of the effects upon cell growth, invasiveness, anchorage-independence, apoptosis and in selected cases tumor formation in mice. In vitro studies using adenocarcinoma cells containing amplified genes of interest of containing overexpressed genes as the result of transfection will be examined for potential targeted therapy and thus providing clinical relevance to identification of specific amplification events. These studies will determine both the identity and frequency of specific genes amplified in esophageal adenocarcinomas and also provide a greater insight into the mechanisms underlying the development and/or progression of this important cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RNF128 Regulation of TP53 in Barrett's Progression
Biomedical Computing and Informatics Strategies for Precision Medicine
  • 批准号:
    9366045
  • 项目类别:
  • 资助金额:
    $35.92万
  • 财政年份:
    2017
  • 负责人:
    DAVID George BEER
  • 依托单位:
RNF128 Regulation of TP53 in Barrett's Progression
Multi-Spectral Targeted Imaging for Early Detection of Cancer in Barrett's Esopha
海外基金